Literature DB >> 8623039

Axis II diagnoses and treatment refractoriness in schizophrenia.

T E Smith1, E Grabstein, M Kentros, S Kulchycky, S Borgaro.   

Abstract

In a previous medical record review study we identified a subset of chronic schizophrenic patients with comorbid Axis II personality disorder diagnoses, who had significantly longer lengths of inpatient stay as compared to schizophrenic patients without Axis II diagnoses. This study describes a detailed review of a subset of these records. Eighteen records of schizophrenic patients with comorbid Axis II diagnoses were matched with records of patients without comorbid diagnoses. Demographic and premorbid data revealed no differences between the groups, indicating that the Axis II diagnoses were markers for current as opposed to past psychopathology. Negative symptoms were lower in the cohort with comorbid Axis II personality disorder diagnoses on admission only, while affective symptomatology was increased in this group throughout treatment. Ratings of personality pathology showed a trend towards significance, with the comorbid group demonstrating greater amounts of maladaptive personality traits. These data support the notion that personality traits may be independent of Axis I symptomatology in chronic schizophrenia, and can influence the course of treatment.

Entities:  

Mesh:

Year:  1996        PMID: 8623039     DOI: 10.1007/bf02244275

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  13 in total

1.  Functional assessment in rehabilitation.

Authors:  C J Wallace
Journal:  Schizophr Bull       Date:  1986       Impact factor: 9.306

2.  An examination of the efficacy of social skills training for chronic schizophrenic patients.

Authors:  A S Bellack; S M Turner; M Hersen; R F Luber
Journal:  Hosp Community Psychiatry       Date:  1984-10

3.  Measurement of premorbid adjustment in chronic schizophrenia.

Authors:  H E Cannon-Spoor; S G Potkin; R J Wyatt
Journal:  Schizophr Bull       Date:  1982       Impact factor: 9.306

4.  An analysis of social competence in schizophrenia.

Authors:  A S Bellack; R L Morrison; J T Wixted; K T Mueser
Journal:  Br J Psychiatry       Date:  1990-06       Impact factor: 9.319

5.  Prevalence and stability of social skill deficits in schizophrenia.

Authors:  K T Mueser; A S Bellack; M S Douglas; R L Morrison
Journal:  Schizophr Res       Date:  1991-09       Impact factor: 4.939

6.  Symptom monitoring in the rehabilitation of schizophrenic patients.

Authors:  D Lukoff; R P Liberman; K H Nuechterlein
Journal:  Schizophr Bull       Date:  1986       Impact factor: 9.306

7.  The role of personality in the treatment of schizophrenic and schizoaffective disorder inpatients: a pilot study.

Authors:  T E Smith; A Deutsch; F Schwartz; K G Terkelsen
Journal:  Bull Menninger Clin       Date:  1993

8.  Social skills training for chronic mental patients.

Authors:  R P Liberman; H K Massel; M D Mosk; S E Wong
Journal:  Hosp Community Psychiatry       Date:  1985-04

Review 9.  Psychosocial rehabilitation and psychiatry in the care of long-term patients.

Authors:  L L Bachrach
Journal:  Am J Psychiatry       Date:  1992-11       Impact factor: 18.112

Review 10.  Social problem solving in schizophrenia.

Authors:  A S Bellack; R L Morrison; K T Mueser
Journal:  Schizophr Bull       Date:  1989       Impact factor: 9.306

View more
  2 in total

1.  Cognitive task performance and symptoms contribute to personality abnormalities in first hospitalized schizophrenia.

Authors:  Ronald J Gurrera; Robert W McCarley; Dean Salisbury
Journal:  J Psychiatr Res       Date:  2014-04-12       Impact factor: 4.791

2.  Co-morbidity of personality disorder in schizophrenia among psychiatric outpatients in China: data from epidemiologic survey in a clinical population.

Authors:  YanYan Wei; TianHong Zhang; Annabelle Chow; YingYing Tang; LiHua Xu; YunFei Dai; XiaoHua Liu; Tong Su; Xiao Pan; Yi Cui; ZiQiang Li; KaiDa Jiang; ZePing Xiao; YunXiang Tang; JiJun Wang
Journal:  BMC Psychiatry       Date:  2016-07-08       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.